Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential by Melissa Bersanelli, Sebastiano Buti

Get full text

Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review by Giulia Mazzaschi, Federico Quaini, Sebastiano Buti

Get full text

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”... by Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti

Get full text

Family history of cancer and DNA damage response genes: Two sides of the same coin? by Alessio Cortellini, Melissa Bersanelli, Corrado Ficorella, Sebastiano Buti

Get full text

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials by Melissa Bersanelli, Fausto Petrelli, Sebastiano Buti, Ignazio Stanganelli

Get full text

Systemic adjuvant therapies in renal cell carcinoma by Sebastiano Buti, Melissa Bersanelli, Maddalena Donini, Andrea Ardizzoni

Get full text

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review by Melissa Bersanelli, Matteo Brunelli, Letizia Gnetti, Umberto Maestroni, Sebastiano Buti

Get full text

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy by Melissa Bersanelli, Sebastiano Buti, Roberta Camisa, Matteo Brighenti, Silvia Lazzarelli, Giancarlo Mazza, Rodolfo Passalacqua

Get full text

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? by Giandomenico Roviello, Sebastiano Buti, Carlo Cattrini, Alessia Mennitto, Carlo Messina, Chiara Airoldi, Gianmarco Vannini, Melissa Bersanelli

Get full text

Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer an... by Tappei Takada, Yukari Uemura, Haruki Kume, Sebastiano Buti, Satoru Taguchi, Taketo Kawai, Katsuhiko Nara, Takehito Yamamoto

Get full text

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis by Carlo Cattrini, Carlo Messina, Chiara Airoldi, Sebastiano Buti, Giandomenico Roviello, Alessia Mennitto, Orazio Caffo, Alessandra Gennari, Melissa Bersanelli

Get full text

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors by Giandomenico Roviello, Martina Catalano, Ugo De Giorgi, Marco Maruzzo, Sebastiano Buti, Sebastiano Buti, Elisabetta Gambale, Giuseppe Procopio, Carlotta Ottanelli, Enrico Caliman, Enrico Caliman, Luca Isella, Pierangela Sepe, Nicole Brighi, Matteo Santoni, Luca Galli, Raffaele Conca, Laura Doni, Lorenzo Antonuzzo, Lorenzo Antonuzzo

Get full text

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors by Filippo G. Dall’Olio, Francesca Abbati, Francesco Facchinetti, Maria Massucci, Barbara Melotti, Anna Squadrilli, Sebastiano Buti, Francesca Formica, Marcello Tiseo, Andrea Ardizzoni

Get full text

Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences by Matteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, Elaine T. Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo L. Rapoport, Enrique Grande, Sebastiano Buti

Get full text

Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate by Ondřej Fiala, Petr Hošek, Hana Korunková, Milan Hora, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti, Jindřich Fínek

Get full text

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? by Satoru Taguchi, Sebastiano Buti, Hiroshi Fukuhara, Masafumi Otsuka, Melissa Bersanelli, Teppei Morikawa, Hideyo Miyazaki, Tohru Nakagawa, Tetsuya Fujimura, Haruki Kume, Yasuhiko Igawa, Yukio Homma

Get full text

Percutaneous Ablation of T1 Renal Masses: Comparative Local Control and Complications after Radiofrequency and Cryoablation by Lorenzo Bertolotti, Federica Segato, Francesco Pagnini, Sebastiano Buti, Andrea Casarin, Antonio Celia, Francesco Ziglioli, Umberto Maestroni, Giuseppe Pedrazzi, Velio Ascenti, Chiara Martini, Calogero Cicero, Massimo De Filippo

Get full text

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma by Martina Catalano, Ugo De Giorgi, Marco Maruzzo, Davide Bimbatti, Sebastiano Buti, Giulia Mazzaschi, Giuseppe Procopio, Matteo Santoni, Luca Galli, Raffaele Conca, Laura Doni, Lorenzo Antonuzzo, Giandomenico Roviello

Get full text

Emostatic-palliative radiotherapy in vescical carcinoma: two case reports by Giovanni Ceccon, Stefano Andreani, Marialuisa Bergamini, Sebastiano Buti, Cristina Dell'Anna, Francesca Ghetti, Stella Gianni, Claudia Grondelli, Elisabetta Lattanzi, Pierluigi Losardo, Moana Manicone, Roberto Rossi, Francesco Salaroli, Nunziata D'Abbiero

Get full text

The Role of CT Imaging in Characterization of Small Renal Masses by Maria Vittoria Bazzocchi, Carlotta Zilioli, Vita Ida Gallone, Claudia Commisso, Lorenzo Bertolotti, Francesco Pagnini, Francesco Ziglioli, Umberto Maestroni, Alberto Aliprandi, Sebastiano Buti, Giuseppe Procopio, Giorgio Ascenti, Chiara Martini, Massimo De Filippo

Get full text